Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
sGaw as an alternative for FEV1 in the measurement of airway responsiveness to methacholine in patients experiencing chronic cough Source: Annual Congress 2011 - Lung function today and tomorrow I Year: 2011
Rapid protective effect of inhaled fluticasone on airway hyperresponsiveness to AMP in patients with fixed airway obstruction due to asthma but not COPD Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020
Postbronchodilator response of small airways after 800 microgrammes of salbutamol in COPD patients Source: International Congress 2016 – Functional assessment of the airways Year: 2016
Influence of basal FEV1 on the response to bronchodilator agents in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Flow-volume responsiveness to bronchodilators in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003
Airway inflammation and inhaled corticosteroids in COPD Source: Eur Respir J, 49 (6) 1700289; 10.1183/13993003.00289-2017 Year: 2017
COPD and airway responsiveness to beta-agonists Source: Annual Congress 2007 - Airway regulation, provocation and monitoring - III Year: 2007
Effect of inhaled tiotropium on tracheobronchial clearance in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001
Comparison of bronchodilatator response of FEV1 and airway resistance Source: Annual Congress 2003 - Assessing airway function: practicalities and clinical applications Year: 2003
Assessment of bronchial hyperreactivity, maximal airway response and response to inhaled corticosteriod treatment in patients with bronchiectasis Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017 Year: 2017
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016 Year: 2017
Changes in airway and tissue mechanics in ventilated COPD patients after nebulized bronchodilator agent Source: Annual Congress 2007 - Advances in respiratory mechanics Year: 2007
Normal lung function and absence of bronchodilator response in children with stable, controlled asthma using inhaled corticosteroids Source: Annual Congress 2006 - New features of paediatric asthma Year: 2006
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003
High doses inhaled salbutamol by MDI in patients with acute bronchial asthma and its cardiopulmonary effects Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009